A four year analysis of variation in use of the anti-neutrophil cytoplasmic antibody (ANCA) test as a screening tool for ANCA-associated systemic vasculitis (AAV) in a teaching hospital.

A four year analysis of variation in use of the anti-neutrophil cytoplasmic antibody (ANCA) test as a screening tool for ANCA-associated systemic vasculitis (AAV) in a teaching hospital.

Detalles Bibliográficos
Main Authors:	McLaren, J, Stimson, R, McRorie, E, Coia, J, Luqmani, R
Formato:	Journal article
Publicado:	2000

Títulos similares

Positive predictive value of anti-neutrophil cytoplasmic antibody (ANCA) testing for ANCA-associated systemic vasculitis (AASV) in a routine clinical setting
por: McLaren, J, et al.
Publicado: (2001)

The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting.
por: McLaren, J, et al.
Publicado: (2001)

CONTEXTUALISING QUALITY OF LIFE IN ANCA ASSOCIATED VASCULITIS (AAV)
por: Basu, N, et al.
Publicado: (2012)

Use of a computerised system to facilitate evaluation of anti-neutrophil cytoplasm (ANCA Associated) vasculitis (AAV) and other forms of systemic vasculitis
por: Luqmani, R, et al.
Publicado: (2017)

Determinants of Poor Quality of Life in ANCA Associated Vasculitis (AAV).
por: Basu, N, et al.
Publicado: (2012)

DEVELOPMENT OF DIAGNOSTIC CRITERIA FOR PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)
por: McLaren, J, et al.
Publicado: (2003)

The UK & Ireland Vasculitis Registry (UKIVAS): Cross-sectional data on the first 2290 Patients with anti-neutrophil cytoplasm (ANCA) associated vasculitis (AAV)
por: Luqmani, R, et al.
Publicado: (2017)

Relapse in Anti-Neutrophil Cytoplasm Antibody (ANCA)–Associated Vasculitis
por: Alan D. Salama
Publicado: (2020-01-01)

Cardiovascular disease incidence and risk factors in ANCA-associated primary systemic vasculitis (AASV)
por: Salisbury, E, et al.
Publicado: (2003)

Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
por: Merkel, P, et al.
Publicado: (2009)

Explaining fatigue in ANCA-associated vasculitis.
por: Basu, N, et al.
Publicado: (2013)

Explaining fatigue in ANCA-associated vasculitis
por: Basu, N, et al.
Publicado: (2013)

INCIDENCE OF NON-FATAL CLINICAL CORONARY EVENTS IN PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)
por: Salisbury, E, et al.
Publicado: (2003)

CARDIOVASCULAR AND CEREBROVASCULAR DISEASE INCIDENCE AND RISK FACTORS IN ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV)
por: Salisbury, E, et al.
Publicado: (2004)

DIAGNOSTIC CRITERIA FOR ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV) IN PATIENTS PRESENTING WITH ACUTE PULMONARY AND/OR RENAL DISEASE
por: McLaren, J, et al.
Publicado: (2004)

Diagnosis and assessment of systemic vasculitis.
por: McLaren, J, et al.
Publicado: (2002)

Pathogenesis and pathology of anti-neutrophil cytoplasmic antibody（ANCA）-associated vasculitis
por: Daisuke Tsukui, et al.
Publicado: (2021-01-01)

Incidence of non-fatal clinical coronary events in primary ANCA-associated systemic vasculitis (aasv)
por: Salisbury, E, et al.
Publicado: (2003)

Outcome measures in ANCA-associated vasculitis.
por: Suppiah, R, et al.
Publicado: (2010)

Different Types of ANCA Determine Different Clinical Phenotypes and Outcome in ANCA-Associated Vasculitis (AAV)
por: Kostas Bantis, et al.
Publicado: (2022-01-01)

Damage assessment in ANCA-associated vasculitis.
por: Bhamra, K, et al.
Publicado: (2012)

The characterisation and determinants of quality of life in ANCA associated vasculitis.
por: Basu, N, et al.
Publicado: (2014)

The characterisation and determinants of quality of life in ANCA associated vasculitis
por: Basu, N, et al.
Publicado: (2014)

Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire
por: Robson, J, et al.
Publicado: (2018)

Maintenance of clinical remission in ANCA-associated vasculitis.
por: Luqmani, R
Publicado: (2013)

The prognostic value of BVAS and VDI in ANCA-AAV
por: Suppiah, R, et al.
Publicado: (2011)

Hallmark trials in ANCA-associated vasculitis (AAV) for the pediatric rheumatologist
por: Jennifer J. Y. Lee, et al.
Publicado: (2019-06-01)

Cutaneous manifestations of ANCA-associated vasculitis
por: Chiesafuxench, Z, et al.
Publicado: (2016)

Diagnosis and management of ANCA associated vasculitis.
por: Berden, A, et al.
Publicado: (2012)

Cardiovascular outcomes in ANCA associated vasculitis
por: Mukhtyar, C, et al.
Publicado: (2008)

Opinion: Maintenance of clinical remission in ANCA-associated vasculitis
por: Luqmani, R
Publicado: (2013)

Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? An audit of 263 patients.
por: Arnold, D, et al.
Publicado: (2010)

CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis
por: Sarvestani Ghafar, et al.
Publicado: (2008-07-01)

Markers for work disability in ANCA-associated vasculitis
por: Basu, N, et al.
Publicado: (2013)

Macrophage Migration Inhibitory Factor (MIF) and Thyroid Hormone Alterations in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)
por: Mårten Wendt, et al.
Publicado: (2013-03-01)

Relapse Predictors in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
por: Katarzyna Wawrzycka-Adamczyk, et al.
Publicado: (2024-08-01)

Neutrophils in ANCA-associated vasculitis: Mechanisms and implications for management
por: Shangqing Ge, et al.
Publicado: (2022-09-01)

Predictors of renal involvement in ANCA associated vasculitis
por: Kronbichler, A, et al.
Publicado: (2018)

ANCA-associated vasculitis: Where can we go from here?
por: Luqmani, R
Publicado: (2010)

Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
por: Zachary S. Wallace, et al.
Publicado: (2019-12-01)